Antigen News and Research

RSS

Survey: 54% of men opt for prostate cancer screening test despite risks

A survey of men age 40 to 74 found that 54 percent said that they would still opt for a popular prostate cancer screening test despite recent recommendations that the test not be performed, finds a new study in American Journal of Preventive Medicine. Only 13 percent said they would choose not to be tested.

9 Jul 2013

ERC awards grants to boost research on vaccines

Vaccination has achieved huge success in controlling many devastating infectious diseases. However, there are still many such diseases, or 'pathogens', against which we cannot generate life-long protective immunity.

9 Jul 2013

GAPVAC aims to develop personalized therapeutic vaccines for cancer

A highly innovative project supported by a €6 million European Union Framework 7 (EU FP7) program grant to develop a novel class of therapeutic cancer vaccines is now under way.

4 Jul 2013

Montreal researchers discover novel research model to study auto-immune diseases

A team of researchers at the IRCM, led by Dr. Javier M. Di Noia in the Immunity and Viral Infections research division, discovered a novel research model for the study of auto-immune diseases. The Montr-al scientists are the first to find a way to separate two important mechanisms that improve the quality of antibodies. This study was featured in a recent issue of The Journal of Immunology.

4 Jul 2013

Assay identifies T cells as most capable of fighting infections and cancers

The idea of fighting infections and even cancers by inducing protective immune responses may now be a step closer to clinical practice. Researchers have removed a major obstacle to widespread use of so-called adoptive transfer therapy, in which a patient receives "killer" immune cells targeting a disease agent. Existing technologies can easily provide T cells that will recognize a specific antigen, but it has been challenging to identify individual cells most likely to succeed in fighting the disease - until now.

4 Jul 2013

Imaxio receives FP7 grant to support the development of S. aureus vaccine

Imaxio, a biopharmaceutical company specialized in vaccines, together with its partners from the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems, is pleased to announce today a European Union award of EUR 5.5 million to support the ‘Bellerophon Project’ consortium to develop a vaccine against Staphylococcus aureus (S. aureus).

3 Jul 2013

NIDA grants $3.3M to design vaccine conferring immunity to nicotine

A chemical component present in the nightshade family of plants is one of the world's most tenaciously addictive substances. It is the nicotine contained in tobacco and found in high concentrations in cigarettes. Smoking remains a global scourge; in the U.S. it is the leading source of preventable death.

3 Jul 2013

Research: Systemic dose of dendritic cells prevent rejection in kidney transplantation

A single systemic dose of special immune cells prevented rejection for almost four months in a preclinical animal model of kidney transplantation, according to experts at the University of Pittsburgh School of Medicine.

1 Jul 2013

Tiny RNA molecules work as powerful regulators of immune response in mammals

A team led by scientists at The Scripps Research Institute (TSRI) has identified a family of tiny RNA molecules that work as powerful regulators of the immune response in mammals. Mice who lack these RNA molecules lose their normal infection-fighting ability, whereas mice that overproduce them develop a fatal autoimmune syndrome.

1 Jul 2013

Physical activity and low calorie food may reduce risk of aggressive prostate cancer

Researchers at UCLA's Jonsson Comprehensive Cancer Center (JCCC) have published the first study on adherence to eight World Cancer Research Fund (WCRF) lifestyle recommendations and aggressive prostate cancer that shows a significantly decreased risk of highly aggressive prostate cancer associated with closer adherence to the recommendations.

30 Jun 2013

RPCI scientists assess safety and efficacy of immunotherapy approach to treat advanced melanoma

A new clinical research study at Roswell Park Cancer Institute (RPCI) will assess the safety and efficacy of a novel immunotherapy approach to treating advanced melanoma. Developed at RPCI by Roswell Park researchers, the investigational vaccine shows promise for treating tumors in patients with stage III/stage IV melanoma, and perhaps as a future therapy for other solid-tumor cancers as well.

30 Jun 2013

Administering immunoglobulins to pregnant women may prevent Rh blood disorder in newborns

Swedish researchers determined that administering anti-D antibodies (immunoglobulins) to pregnant women who were Rhesus D (RhD) negative could prevent hemolytic disease in the infant.

27 Jun 2013

Study: Active surveillance does not appear to be good idea for black men with prostate cancer

A Johns Hopkins study of more than 1,800 men ages 52 to 62 suggests that African-Americans diagnosed with very-low-risk prostate cancers are much more likely than white men to actually have aggressive disease that goes unrecognized with current diagnostic approaches.

26 Jun 2013

Study examines increased use of new technologies for prostate cancer treatment

Use of advanced treatment technologies for prostate cancer, such as intensity-modulated radiotherapy and robotic prostatectomy, has increased among men with low-risk disease, high risk of noncancer mortality, or both, a population of patients who are unlikely to benefit from these treatments, according to a study in the June 26 issue of JAMA.

26 Jun 2013

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

Morphotek, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened enrollment in a Phase I clinical study with MORAb-066 in patients with advanced or metastatic breast, pancreatic, colorectal or non-small cell lung cancer (adenocarcinoma) malignancies.

26 Jun 2013

New streamlined method harnesses tumor-infiltrating lymphocytes to improve outcomes

Jamie K. Teer, Ph.D., assistant member of the Cancer Biology and Evolution Program at Moffitt Cancer Center, and colleagues have developed a new streamlined method to rapidly identify the genetic changes in small protein fragments unique to melanoma cancer cells.

26 Jun 2013

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has submitted an Application for Orphan Drug Designation with the U.S. Food and Drug Administration Office of Orphan Products Development for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus-associated anal cancer.

25 Jun 2013

Researchers test modified dendritic cells in patients with melanoma

In this issue of the Journal of Clinical Investigation, researchers led by Scott Pruitt at Duke University and Merck Research Laboratories report on a human clinical trial in which modified dendritic cells, a component of the immune system, were tested in patients with melanoma.

25 Jun 2013

Researchers find elevated antibodies to gluten proteins of wheat in children with autism

Researchers have found elevated antibodies to gluten proteins of wheat in children with autism in comparison to those without autism. The results also indicated an association between the elevated antibodies and the presence of gastrointestinal symptoms in the affected children.

21 Jun 2013

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago's plant-based manufacturing platform.

20 Jun 2013

Antigen News and Research

Survey: 54% of men opt for prostate cancer screening test despite risks

ERC awards grants to boost research on vaccines

GAPVAC aims to develop personalized therapeutic vaccines for cancer

Montreal researchers discover novel research model to study auto-immune diseases

Assay identifies T cells as most capable of fighting infections and cancers

Imaxio receives FP7 grant to support the development of S. aureus vaccine

NIDA grants $3.3M to design vaccine conferring immunity to nicotine

Research: Systemic dose of dendritic cells prevent rejection in kidney transplantation

Tiny RNA molecules work as powerful regulators of immune response in mammals

Physical activity and low calorie food may reduce risk of aggressive prostate cancer

RPCI scientists assess safety and efficacy of immunotherapy approach to treat advanced melanoma

Administering immunoglobulins to pregnant women may prevent Rh blood disorder in newborns

Study: Active surveillance does not appear to be good idea for black men with prostate cancer

Study examines increased use of new technologies for prostate cancer treatment

Sarah Cannon Research Institute opens enrollment in Phase I clinical study with MORAb-066

New streamlined method harnesses tumor-infiltrating lymphocytes to improve outcomes

Advaxis seeks ADXS-HPV Orphan Drug Designation for treatment of HPV-associated anal cancer

Researchers test modified dendritic cells in patients with melanoma

Researchers find elevated antibodies to gluten proteins of wheat in children with autism

Medicago produces Rotavirus VLP vaccine candidate using plant-based manufacturing platform

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News